LUCAS (Lucentis Compared to Avastin Study) (LUCAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01127360|
Recruitment Status : Completed
First Posted : May 20, 2010
Last Update Posted : January 16, 2015
Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over 50 years of age. Bevacizumab and ranibizumab are two agents developed by the American pharmaceutical corporation Genentech, both of which inhibit blood vessel growth factors. These drugs, when injected intraocularly, reduce the pathological growth of blood vessels in the macular area of the eye. Bevacizumab (Avastin) is an antibody developed for intravenous treatment of metastasized colon cancer. Ranibizumab (Lucentis) is an antibody fragment developed from a similar antibody. It was introduced 2006 as an effective treatment for wet AMD. Treatment costs are, however, up to 50 times higher compared to use of bevacizumab. Avastin has shown similar effects to ranibizumab, and has been used off-label in many countries, both before and after Lucentis received approval. There is thus a recognized need for large randomized studies to garner proper scientific proof of Avastin's effectiveness regarding exudative AMD.
LUCAS is a randomized multicenter study, performed in Norway, comparing ranibizumab and bevacizumab use for AMD. The goal of the study was to demonstrate if the two agents were equivalent regarding both efficacy and safety. A total of 441 patients with objective evidence of wet AMD were randomized to a double-blind treatment with ranibizumab or bevacizumab over the course of 2 years. The treatment interval was determined by a "Treat and Extend" protocol.
|Condition or disease||Intervention/treatment||Phase|
|Exudative Age-related Macular Degeneration||Drug: Bevacizumab Drug: Ranibizumab||Phase 4|
LUCAS (LUcentis Compared to Avastin Study) A randomized, double-blind, prospective multicenter study comparing the effect of intravitreal injection of bevacizumab (Avastin) to ranibizumab (Lucentis) when given to patients with exudative (wet) age-related macular degeneration in Norway.
Version: 4, Protocol: 166-09, EudraCT: 2008-004225-41
LUCAS is a prospective, randomized, multicenter study comparing the effects of intravitreal injection of bevacizumab (Avastin) with ranibizumab (Lucentis) when given to patients with exudative (wet) AMD in Norway.
The study will include 420 patients to be recruited starting March 2009. The study will continue for 2 years after completed enrollment.
LUCAS is a multicenter, randomized, double-blind study, with 1:1 parallel groups treated with either bevacizumab (Avastin) 0.05 ml (25 mg/ml) or ranibizumab (Lucentis) 0,05 ml (10 mg/ml). The drug is injected intravitreally according to an "inject and extend" principle (5).
Randomization will be stratified by center and performed with minimization according to prognostic factors.
Bevacizumab (Avastin) will be given as an intravitreal injection of 0.05ml (25 mg/ml) from a vial containing 4 ml.
Ranibizumab (Lucentis) will be given as an intravitreal injection of 0.05 ml (10 mg/ml) from a vial containing 0.23 ml.
Follow-up and treatment will follow a principle called "inject and extend." This connotes the following: initial follow-up and injection with a 4 week intervals until the macula is dry. When dry, then follow-up and injection will be increased 2 weeks at a time. If the patient has a recurrence of wet AMD, then the interval is reduced by 2 weeks at a time until the macula is once again dry. The shortest interval is 4 weeks. When once again extending, the treatment interval shall not be as long as the interval of the original recurrence, as this could confer risk for new activity. Therefore further follow-up and injection occurs at the "ideal" interval which is hereby defined as being 2 weeks less than that of the original recurrence. With this method, the patient receives an injection at each follow-up, presuming that no complications occur. The maximum interval is limited to 12 weeks. Treatment will continue for 2 years. After the study is completed, then the patient is to be offered continued treatment, in accordance with the ophthalmology department's routines, If there is no response to treatment after 3 injections with a 4 week interval, then the patient shall be removed from the study and be offered alternative treatment, such as combination treatment with photodynamic therapy (PDT).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||420 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2014|
Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
Other Name: Avastin
Other Name: Lucentis
Active Comparator: Ranibizumab
Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
Other Name: Avastin
Other Name: Lucentis
- Mean change in VA at 1 and 2 years as measured with the ETDRS chart [ Time Frame: After 1 and 2 years ]Mean change in VA at 1 and 2 years as measured with the ETDRS chart (with a non-inferiority limit of 5 letters)
- Number of treatments. [ Time Frame: After 1 and 2 years ]Number of treatments.
- Proportion of patients losing fewer than 15 letters on ETDRS chart [ Time Frame: After 1 and 2 years ]Proportion of patients losing fewer than 15 letters on ETDRS chart
- Macular morphology as measured by FA and OCT after 2 years. [ Time Frame: After 2 years ]Macular morphology as measured by FA and OCT after 2 years.
- Adverse events [ Time Frame: 2 years ]Frequency of ophthalmological and other health related adverse events during the 2 year study.
- Number of non-responders. [ Time Frame: After 2 years ]Number of non-responders.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01127360
|Department of Ophthalmology, Oslo University Hospital|
|Oslo, Norway, 0407|
|Study Director:||Andreas Moan||Director of Research at Oslo University Hospital|
|Study Chair:||Ragnheidur Bragadottir, MD. PhD.||Department of Ophthtalmology, Oslo University Hospital|
|Principal Investigator:||Karina Berg, MD.||Department of Ophthalmology, Oslo University Hospital|
|Study Chair:||Terje Pedersen, Professor||Department of Preventative Medicine, Oslo University Hospital|